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Abstract: 
Hepatitis c infection caused by Hepatitis c virus (HBV) is a major world-wide health problem. Current therapeutic 
strategies rarely eradicate HBV infections and fail to attain complete cure. There is urgent need to develop advanced 
treatment strategies to successfully remove HBV infection and eliminate hidden reservoirs of virus. Recently, the 
establishment of a novel RNA-guided gene editing tool known as the clustered regularly interspaced short palindromic 
repeats/CRISPR-associated nuclease 9 (CRISPR/Cas9) system, has significantly enabled site-specific mutagenesis 
and characterizes a very beneficial possible therapeutic means for diseases which includes extermination of invasive 
pathogens e.g. HBV. This review highlights the recent developments in the use of CRISPR/Cas9 to specifically target 
HBV DNA sequences for inhibition of replication of HBV and to bring mutations in viral genome, animal models. 
Benefits, restrictions and viable solutions, and proposed guidelines for forthcoming study in CRISPR/Cas9 are 
described to highlight the chances and challenges for curative therapy of chronic hepatitis B infection. 
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350 million persons are affected with hepatitis c virus 
(HBV) globally. Near about 10% of patients have 
chronic type of hepatitis c. Chronic hepatitis c (CHB) 
is a severe condition that may lead towards more 
critical symptoms like cirrhosis and hepatocellular 
carcinoma(Kennedy et al., 2015b). According to 
estimation 700 thousand patients infected with HBV 
develop chronic infection and died each year. From 
previous 20 years many antiviral therapies are in 
practice to suppress HBV infection but these are not 
effective to eliminate the infection(Dienstag, 2008). 
HBV is member of Hepadnaviridae virus family and 
replicates inside the hepatocytes of human. The HBV 
genome contains DNA which is partially double-
stranded(Gebbing et al., 2015). It comprises of a 
complete coding strand and other is incomplete non-
coding strand known as relaxed circular DNA 
(rcDNA)(Ayoub and Keeffe, 2011). When virus 
infects hepatocytes, rcDNA from virus is transported 
towards the nucleus(Mehvish and Qadir, 2011). Where 
it is transformed into covalently closed circular DNA 
(cDNA). cDNA works as the template for transcription 
of viral pregenomic RNA (pgRNA) and protein coding 
mRNAs(Kennedy et al., 2015b). After transcription 
viral transcripts are moved into the cytoplasm where 
these are translated into viral proteins. Then, the which 
consists of viral core and polymerase protein, reverse 
transcribe and form a new viral rcDNA(Li et al., 
2017). Enveloped nucleocapsids which contains DNA 
secreted into cytoplasm as progeny virus or sometimes 
transported back to the nucleus for amplification of the 
cccDNA pool(Peng et al., 2015). 
 
Present drugs against HBV include interferon-α (IFN-
α), nucleotide/nucleoside analogues used to adjust the 
immune response between host and virus(Perz et al., 
2006). Due to limited efficiency IFN-α cannot give in 
high dosage because patients cannot tolerate high 
dose. Although nucleoside analogues are used to 
control the infection but they cannot functionally cure 
HBV(Schädler and Hildt, 2009). cccDNA is 
persistent, so long-term treatment required for 
patients, which is expensive and develop drug 
resistance in patients(Niaz et al., 2010). HBV is a 
retrovirus, it can cause mutations during the reverse 
transcription which enhances their chance to be safe 
from removal by traditional antiviral drug 
treatment(Block et al., 2015). cccDNA have amazing 
stability and cannot disrupt by current antiviral 
therapies. More efficient and non-toxic methods are 
required for clearance of the cccDNA(Kennedy et al., 
2015a). Recently, numerous newgenome-editing 
methods have been developed, which based on 
sequence-specific endonucleases like zinc-finger 
nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs) and the most recent CRISPR 
(clustered regularly interspaced short palindromic 
repeats)/Cas9 (CRISPR associated 9) system(Li et al., 
2017). The CRISPR/Cas9 system is basically natural 
defence mechanism of bacteria and archaea against 
virus. The Cas9 protein of type II CRISPR/Cas system 
has ability to cleave DNA at specific site with the help 
of CRISPR RNA (crRNA) and trans-activating 
CRISPR RNA (tracrRNA)(Lin et al., 2015). PAM 
sequence (NGG) necessary for Cas9 protein to cleave 
the DNA. PAM sequence present downstream of the 
target DNA. It produces DNA breaks in double 
stranded DNA known as double strand breaks (DSBs). 
These DSBs are repaired by homologous direct repair 
mechanism or by non-homologous end-joining 
(NHEJ) repair mechanism(Liu et al., 2015). The NHEJ 
mechanism is error-prone and can create 
insertions/deletions or other mutations during repair 
which cause frameshift mutations and ultimately gene 
knockout(Qadir, 2011). Moreover, there is also a 
chance that the crRNA–tracrRNA complex can be 
merged into a single guide RNA (gRNA)(Mei et al., 
2016). For cleavage CRISPR/Cas9 system needs a 
single strand that matches with the target DNA of 
virus. CRISPR/Cas9 system is convenient as 
compared to ZFN- and TALEN genome editing 
methods. That is recent advances in genome editing 
are based on the CRIPSR/Cas9 system(Moyo et al., 
2017). 
 
The gRNA-guided CRISPR/Cas9 (gRNA/Cas9) 
system has been effectively used in numerous areas of 
biological and medical sciences. This technique also 
has application in virus research, for example for the 
genome editing of Epstein–Barrvirus and herpes 
simplex virus, and the abolition of human 
immunodeficiency virus (HIV) infection. This review 
provides the information that the gRNA/Cas9 system 
could greatly inhibit replication of HBV(Moyo et al., 
2017). Inhibition can be in vitro and in vivo in which 
the viral genome directly disrupts by HBV specific 
gRNAs. Furthermore, HBV-specific gRNA/Cas9 
systems can prevent the replications of HBV of 
different strains in cells. A single gRNA/Cas9 system 
can  significantly reduce the viral genome and 
combination of different gRNA/Cas9 systems used to 
eliminate the persistent viral genome(Seeger and 
Mason, 2015). 
 
This review demonstrates the prospect to inhibit 
replication of virus and clearance of persistent cDNA 
of HBV that is used for functional anti-HBV therapy, 
reduce the drug resistance which occur due to 
mutations during replication(Zhu etal., 2015) One of 
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the major advantage of CRISPR/Cas9 over other 
approaches for gene editing is that its capacity of 
multiplex targeting which provides a way for several 
disruptions, insertions, and deletions with greater 
efficiency and less cost. Thus, for improved 
destruction efficiency in the genome of HBV for 
multiple genomic editing, the blend of diverse site 
specific sgRNAs that can target several  sequences will 




MATERIALS AND METHODS: 
Table 1: Questionnaire to evaluate awareness about etiology of Hepatitis C 
Hepatitis C is a  Yes   No 
1. Viral disease   
2. Bacterial disease    
3. Fungal disease   
4. Genetic disease   
5. Metabolic disease   
Ever suffered from Hepatitis C   
6. You   
7. Your family    
8. Your relative    
9. Your neighbor   
10. Your friend   
Hepatitis C is transmitted by   
11. Contacts or blood transfusion   
12. From parents to offspring   
Hepatitis C may be treated by    
13. Medicines   
14. Surgery    




Table 1: Questionnaire to evaluate awareness about etiology of Hepatitis A 
Hepatitis C is a  Yes   No 
1. Viral disease   
2. Bacterial disease    
3. Fungal disease   
4. Genetic disease   
5. Metabolic disease   
 
Table 2: Questionnaire to evaluate views about prevalence of Hepatitis C 
Ever suffered from Hepatitis C  Yes   No 
1. You   
2. Your family    
3. Your relative   
4. Your neighbor    
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3: Questionnaire to evaluate views about transmission of Hepatitis C 
Hepatitis A is transmitted by  Yes   No 
1. Contacts Table or blood transfusion   
    
 
Table 4: Questionnaire to evaluate views about Hope for Hepatitis C 
Hepatitis C may be treated by  Yes   No 
1. Medicines   
2. Surgery    






Table 5: Awareness about etiology of Hepatitis C: Views of Postgraduate Biology Students 
 
 
Questions            Male Female Total 
Yes No Yes No Yes No 
1. Viral disease 92% 8% 96% 4% 96% 4% 
2. Bacterial disease  41% 59% 15% 85% 30% 70% 
3. Fungal disease 70% 30% 73% 27% 30% 70% 
4. Genetic disease 37% 63% 70% 30% 34% 74% 






Role of CRISPR/Cas9 to Target cDNA and 
Inhibition of HBV Replication: 
Genome of the HBV has four long open reading 
frames that are surface, core, polymerase, and X 
protein. These are translated into only seven proteins 
which are very important for replication of virus. For 
suppression of viral gene expression and replication, 
targeting any 1 of 7 proteins is enough. Many 
examples are present in which HBV genome is 
targeted with CRISPR/Cas9 system. A scientist 
reported that the CRISPR/Cas9 system can disrupt the 
viral genome both in vitro and in vivo(Saayman et al., 
2015). Cas9/sgRNA specific for HBV can 
significantly decrease the construction of HBV core 
and surface antigen, when a complex of Cas9 and 
HBV expression plasmid transfected into 
carcinoma cells derived from Huh7 
hepatocyte(Schiffer et al., 2012). Moreover, 
CRISPR/Cas9 system efficiently decrease the 
intrahepatic HBV-expressing vectors level and surface 
antigen serum levels in an HBV infected mouse 
model(Zhen et al., 2015). Transduction of Cas9 and 
HBV-specific gRNAs by using lentiviral, effective 
inhibition of HBV DNA and cccDNA is 
observed(Schweitzer et al., 2015). According to a 
study levels of total HBV viral DNA decline up to 
~1000-fold by the CRISPR/Cas9 and cccDNA level 
declines up to ~10-folds. According to Seeger and 
Sohn HBV contaminations can be repressed up to 
eightfold by HBV-specific guide RNAs in NTCP 
expressing HepG2 cells. In alternative study, Liu et al. 
stated that HBV-specific gRNA/Cas9 can prevent the 
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HBV replication of diverse genotypes equally in vitro 
and in vivo, it is due to removal and fallible repair of 
viral DNA templates(Seeger and Sohn, 2014). This 
system can efficiently impede levels of HBV DNA and 
HBsAg countenance in liver of mouse. According to 
Dong et al. the CRISPR/Cas system can be used for 
impeding intracellular cccDNA. Ramanan et al. 
showed that sgRNAs targeting conserved regions of 
HBV cause strong inhibition of virus replication both 
in vitro and in vivo, and extended this antiviral activity 
to virus isolated from patients(Kennedy et al., 2015c). 
Continuous expression of Cas9/sgRNA shows rapid 
decline of persistent cccDNA and HBV proteins in a 
denovo infection model. Recently, Karimova et al. 
demonstrated that an advanced CRISPR/Cas9 nickase 
system has capability to disturb both HBV cccDNA 
and fused HBV sequences in HeLa and HEK293 cell 
lines(Shalem et al., 2014). In short, these findings 
demonstrate the successfully use of the CRISPR/Cas9 
system in destroying HBV cDNA both in vitro and in 
vivo, and shown the therapeutic approach of 
CRISPR/Cas9 in both acute and chronic HBV 
infection(Shen et al., 2014). 
 
Challenges for the CRISPR/Cas9 system as a Novel 
HBV therapeutic approach: 
 
Before clinical application of CRISPR/Cas9 systems 
for HBV treatment, significant problems are needed to 
be addressed. Major concern is related to capability of 
extermination of all viruses(Hai et al., 2014). Yet, by 
Ramanan et al. achieved the best result for cleavage of 
HBV via CRISPR/Cas9. The suppression of cDNA is 
about 92% in cultured cells. One of the major 
challenge is presence of HBV DNA in different tissues 
external the liver and replication of HBV in different 
cell lines(Kennedy and Cullen, 2015). To eradicate 
HBV, it is important that nucleases transported to 
every single infected cell in liver and outside the liver 
reservoirs of virus. For sustained in vivo anti-HBV 
action, an effective vehicle for delivery must be 
used(Schweitzer et al., 2015). 
 
Recombinant adeno-associated viral vectors (rAAVs) 
are considered as best delivering vehicle for 
CRISPR/Cas9 due to the less immune response, non 
incorporating nature, and high infection efficacy(Yin 
et al., 2014). Packaging difficulty can be resolved by 
enchanting benefit of a split-Cas9 system or by means 
of a smaller Cas9 orthologs e.g. SaCas9 from 
Staphylococcus aureus, which is shorter than 1 
kb(Seeger and Sohn, 2014). The second issue of 
CRISPR/Cas9 system is the probable off-target 
effects. Previously published data show that the rate of 
off-target activity of CRISPR/Cas9 system is high, 
even in case of sgRNAs which have almost five 
nucleotides mismatches(Shalem et al., 2014). 
Numerous methods have been established to decrease 
off-target effects. 
 
One approach is “paired nicking”. It reduces the off-
target delivery by using two spaced gRNAs and a 
mutated Cas9 (Cas9n). Both can cleave single-strand 
DNA and instead of producing DSBs a nick is formed 
on both DNA strands. Nicks further repaired 
accurately by the cell repair mechanism. Paired 
nicking reduced off-target effect by 50–1,000 fold in 
cell lines comparing to the wild-type Cas9. 
 
2nd strategy is the use of Truncate sgRNAs at the end 
of the complementary targeting sequence. Fu et al. 
described that a short sgRNAs of 17 or 18 nucleotides 
may increase specificity for target sequence by more 
than 5000-fold 
without decreasing the on-target activity. fCas9 is 
another modified Cas9 which designed by fusing of 
catalytically inactive Cas9 and Fok I nuclease. 
Specificity of fCas9 system increased by140-fold than 
normal Cas9 by increasing targeting sequences in 
human cells(Xu et al., 2014). But, these methods 
remain less effective. Selection of appropriate target 
sites in the genome of HBV has greater concern. The 
main issue of Nucleoside/Nucleotide analogue therapy 
is the occurrence of HB variants which are therapy-
resistant. CRISPR/Cas9 system provides specific 
sequence recognition(Shen et al., 2014). In case of 
high viral, the CRISPR/Cas9 provide a pool of 
therapy-resistant viruses which can reestablish 
infection. So, overlapping of targeting sequence with 
regions like (Y)-methionine (M)-aspartic acid (D)-
aspartic acid (D) (YMDD) motif should avoid. 
 
Importantly, due to high sequence deviation, genome 
of HBV is classified into eight genotypes A–H(Yang 
and Kao, 2014). Use of multiple CRISPR/Cas9 
constructs and targeting of highly conserved regions 
between diverse viral genotypes are good approaches 
for reducing the issue of current and de novo 
mutations(Komatsu, 2014). Persistent incorporated 
linearized viral DNA, cleaves by the CRISPR/Cas9 
system. The incorporation of sub genomic viral DNA 
parts into genome of host is common in hepatocellular 
carcinoma or chronically infected patients. Host gene 
function can be disrupted by cleavage of incorporated 
viral DNA which lead to insertion/deletion mutation in 
host genome. The undesirable side effects must be 
evaluated carefully(Kennedy et al., 2015c). 
 
Potential Target for HBV in Gene Editing Therapy 
with CRISPR/Cas9: 
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Different genome editing strategies have been 
currently used as tool against numerous human 
viruses. In curative HIV research field, studies 
presented that CD4+ T cells with chemokine (CC 
motif) receptor 5 (CCR5)-disturbed by nucleases show 
resistance against HIV-1 infection. ZFNs which 
disrupt CCR5 is under phase I clinical trials, is 
breakthrough(Wyman and Kanaar, 2006). Recently 
Sodium taurocholate co-transporting polypeptide 
identified as an entrance receptor of HBV and HDV 
which facilitates the transportation of bile acids and 
other molecules from portal circulation. One class of 
the indirect anti-HBV agents in progress are entrance 
inhibitors, which target the HBV receptor NTCP(Yan 
et al., 2013). With the inspiring result of nucleases 
based CCR5 gene editing therapy, it stances to reason 
behind use of CRISPR/Cas9 for disruption of NTCP 
expression block the entrance of HBV and stop the 
spread of viral infection(Yang et al., 2013). Yet again, 
although no reports of dangerous diseases linked with 
faults in the NTCP gene have been available yet, the 
possible modification of function of gene and NTCP 




The CRISPR/Cas9 technology has enormously 
advanced our capability to edit the and provides a new 
era of gene therapies for treatment of diseases. 
 
Although it still in a clinical trial stage, CRISPR/Cas9 
system used both in vitro and in vivo way for 
inhibition of HBV replication and gene expression, 
and may establish a new beneficial strategy for HBV 
infection. Currently use of combined  CRISPR/Cas9 
therapy and RT inhibitors may attain the maximum 
rates of viral response. Still many difficulties remain 
to evaluate including safety and effective delivery of 
the system, CRISPR/Cas9 strategies provide immense 
potential to cure chronic HBV infection. Experimental 
research has revealed that CRISPR/Cas9 cleaves 
episomal cccDNA, decreases pgRNA, and inhibit viral 
proteins without any cytotoxic effects, providing 
considerable evidence that CRISPR/Cas9 strategy is a 
promising tool with the possibility to work as an 
efficient HBV infections treatment and to exterminate 
cccDNA. But it is significant to be careful around the 
challenges that reduce the practicability and security 
of these innovative methods. Many problems should 
be resolved. Many improvements are required to 
achieve effective and safer therapeutic techniques to 
use CRISPR/Cas9 technology for eradication of 
cccDNA and inhibition of HBV. 
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